Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

February 28, 2011

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Jones Kenneth T

2. Date of Event Requiring Statement (Month/Day/Year)
08/08/2023

3. Issuer Name and Ticker or Trading Symbol
Zynerba Pharmaceuticals, Inc. [ZYNE]

(Last)

(First)

(Middle)

C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
See Remarks

5. If Amendment, Date Original Filed (Month/Day/Year)

(Street)

DEVON, PA 19333

6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	79,025	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	03/28/2027	Common Stock	35,000	$ 20.02	D
Stock Option (right to buy)	⁽¹⁾	01/11/2028	Common Stock	24,000	$ 11.71	D
Stock Option (right to buy)	⁽¹⁾	01/24/2029	Common Stock	20,000	$ 3.65	D
Stock Option (right to buy)	⁽²⁾	01/30/2030	Common Stock	22,500	$ 5.05	D
Stock Option (right to buy)	⁽³⁾	01/21/2031	Common Stock	20,000	$ 3.58	D
Stock Option (right to buy)	⁽⁴⁾	01/26/2032	Common Stock	21,250	$ 2.41	D

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Jones Kenneth T C/O ZYNERBA PHARMACEUTICALS, INC. 80 W. LANCASTER AVENUE, SUITE 300 DEVON, PA 19333			See Remarks

Signatures

/s/ Albert P. Parker, Attorney-in-Fact		08/15/2023
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The stock option is fully vested and immediately exercisable.
(2)	The stock option vests 25% on January 30, 2021, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.
(3)	The stock option vests 25% on January 21, 2022, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.
(4)	The stock option vests 25% on January 26, 2023, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.
Remarks: Vice President, Corporate Controller and Interim Chief Financial Officer; Exhibit List - Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.